PADI4 and autoimmune disease: The pan-PAD inhibitor, Cl-amidine, [29,30] is well established and has already been assessed in a number of in vitro and in vivo models, including autoimmune diseases, cancer models and CNS neuroprotection with potent neuroprotective effects [3,6,7,8,20,31,32,33,34,35].